Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226367 · ClinicalTrials.gov registry record · NA
Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD
A NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- NA
- Development phase
- 158
- Enrollment target
NCT02226367 is a NA study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 158 participants.
The verdict
NCT02226367, a NA study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate if the drug prazosin: * will decrease alcohol use in active duty members of the military who served in Iraq and/or Afghanistan and * determine if presence or absence of posttraumatic stress disorder affects treatment.
Interventions
- DRUG placebo
- DRUG prazosin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-10-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226367
The ClinicalTrials.gov registry entry for NCT02226367 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02226367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02226367 about?
NCT02226367 is a clinical study titled "Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD". The purpose of the study is to evaluate if the drug prazosin: * will decrease alcohol use in active duty members of the military who served in Iraq and/or Afghanistan and * determine if presence or absence of posttraumatic stress disorder affects treatment.
What is the current status of trial NCT02226367?
This trial is currently completed. It is a NA study. The enrollment target is 158 participants. The study started on 2015-01. Estimated completion is 2018-10-20.
What interventions are being tested in trial NCT02226367?
The interventions under investigation include: placebo (DRUG), prazosin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02226367?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.